Although we find B7-H3 to be more robustly expressed in solid tumors than hematologic malignancies, it is still worthwhile to note that B7-H3 remains an attractive target currently being pursued in multiple myeloma and acute myeloid leukemia (37). This evidence concerns the gene CD276 and plasma cell myeloma.